VOYA INDEX SOLUTION 2050 PORTFOLIO - Voya

Shareclass
VOYA INDEX SOLUTION 2050 PORTFOLIO Class ADV (IDXPX)
Type
Open-end mutual fund
Manager
Target date
VOYA INDEX SOLUTION PORTFOLIO - Voya
Gender equality score
Gender equality score

55
/ 100 points
Overall score
Average Equileap Gender Equality Score of fund holdings, weighted by market value
Peer rank
Group ranking

A
82
percentile

Universe: Groups

Group: Allocation

Ranking: 119 out of 651 funds


See more funds from this group
 All funds
 Groups
Gender balance in leadership and workforce
Gender balance in leadership and workforce
26/40
See the score criteria
Equal compensation and work life balance
Equal compensation and work life balance
10/30
See the score criteria
Policies promoting gender equality
Policies promoting gender equality
18/20
See the score criteria
Commitment, transparency, and accountability
Commitment, transparency, and accountability
1/10
See the score criteria






Top scoring holdings
Top scoring holdings
The top 10 holdings in this portfolio with the best scores on the Equileap Gender Scorecard. In the case of ties, the holding with more assets invested is listed higher.
  • 1. Transurban Group
    0.04% of assets
    $378,949 invested
  • 2. QBE Insurance Group Ltd
    0.03% of assets
    $257,090 invested
  • 3. Allianz SE
    0.23% of assets
    $2.3M invested
  • 4. International Flavors & Fragrances Inc
    0.02% of assets
    $234,730 invested
  • 5. AstraZeneca PLC
    0.37% of assets
    $3.69M invested
  • 6. Qantas Airways Ltd
    <0.01% of assets
    $65,867 invested
  • 7. ASX Ltd
    <0.01% of assets
    $85,549 invested
  • 8. Standard Chartered PLC
    0.06% of assets
    $610,574 invested
  • 9. CAR Group Ltd
    <0.01% of assets
    $99,662 invested
  • 10. Aena SME SA
    0.03% of assets
    $269,452 invested
Bottom scoring holdings
Bottom scoring holdings
The bottom 10 holdings in this portfolio with the worst scores on the Equileap Gender Scorecard. In the case of ties, the holding with more assets invested is listed higher.
  • 1. Taiwan Semiconductor Manufacturing Co Ltd
    0.78% of assets
    $7.86M invested
  • 2. Samsung Electronics Co Ltd
    0.26% of assets
    $2.57M invested
  • 3. Reliance Industries Ltd
    0.07% of assets
    $693,131 invested
  • 4. China Construction Bank Corp
    0.06% of assets
    $619,668 invested
  • 5. Bharti Airtel Ltd
    0.04% of assets
    $390,777 invested
  • 6. Ping An Insurance Group Co of China Ltd
    0.04% of assets
    $357,521 invested
  • 7. Industrial & Commercial Bank of China Ltd
    0.03% of assets
    $335,160 invested
  • 8. Vale SA
    0.03% of assets
    $311,192 invested
  • 9. Bank of China Ltd
    0.03% of assets
    $262,121 invested
  • 10. Saudi Arabian Oil Co
    0.02% of assets
    $247,288 invested
Find sustainably-invested mutual funds and ETFs



Search for funds from your 401(k), retirement plan, or personal portfolio
What's next?
Learn how to make a change and move your money
Get started with our action toolkit
Ask your employer about gender-lens investing in your retirement plan
Find socially responsible funds that invest in gender equality
Learn more about As You Sow's Invest Your Values program
Visit Fossil Free Funds to measure the climate risk of this portfolio
More from Invest Your Values
See how mutual funds and ETFs are rated on issues ranging from fossil fuels, to deforestation, gender equality, guns, prisons, weapons, and tobacco

Disclaimer: As You Sow is not an investment adviser

As You Sow is not an investment adviser as that term is defined under federal and state (California) laws and regulations. As You Sow is a tax-exempt, nonprofit organization dedicated to educating and empowering shareholders to change corporations for the good through the collection, analysis and dissemination of relevant information to the public, free of charge. As You Sow does not provide financial planning, legal or tax advice. Nothing on this website shall constitute or be construed as an offering of financial instruments, or as investment advice or investment recommendations.
See our full disclaimer